

**University of California, San Francisco**  
**CURRICULUM VITAE**

**Name:** Bradley Alden Stohr, MD, PhD

**Position:** Associate Professor of Clinical Pathology, Step 1  
Pathology  
School of Medicine

**Address:** University of California  
Pathology, Box 0466  
1825 4th Street, Room M2371  
San Francisco, CA 94143

**EDUCATION**

1991 - 1995	Swarthmore College, Swarthmore, PA	B.A.	Biology	
1996 - 2003	Duke University School of Medicine	M.D.		
1998 - 2002	Duke University	Ph.D.	Microbiology	Advisor: Kenneth Kreuzer
2003 - 2006	University of California, San Francisco	Resident/Fellow	Pathology	
2005 - 2008	University of California, San Francisco	Postdoctoral Fellow	Cancer Biology	Advisor: Elizabeth Blackburn

**LICENSES, CERTIFICATION**

2005	Medical Licensure, California
2006	Board Certification, Anatomic Pathology

**PRINCIPAL POSITIONS HELD**

2008 - 2010	University of California, San Francisco	Clinical Instructor	Pathology
2010 - 2017	University of California, San Francisco	Assistant Professor	Pathology
2017 - present	University of California, San Francisco	Associate Professor	Pathology

**HONORS AND AWARDS**

1995	Phi Beta Kappa
------	----------------

1995	Sigma Xi
1996	Medical Scientist Training Program Fellowship
2005	American Cancer Society Postdoctoral Fellowship
2009	Mentored Clinical Scientist Development Award (K08)
2010	UCSF Program for Breakthrough Biomedical Research New Frontier Research Award
2012	UC Cancer Research Coordinating Committee Cancer Research Award
2014	Nomination, Essential Core Teaching Award, UCSF Medical School
2015	American Cancer Society Research Scholar Grant
2017	Stuart Lindsay Endowed Professorship in Experimental Pathology III
2018	UCSF Pathology Resident/Fellow Teaching Award
2018	Medical School Bridges Curriculum Foundations 1 and 2 Teaching Award for Excellence in Small Group Instruction
2018	The Haile T. Debas Academy of Medical Educators Excellence in Teaching Award

## **CLINICAL ACTIVITIES**

My clinical service at Mission Bay Hospital is comprised of two main components. First, I sign out surgical pathology cases with a focus on urologic and head and neck pathology. Second, I sign out UCSF500 cancer gene panel clinical cases.

## **PROFESSIONAL ACTIVITIES**

### **MEMBERSHIPS**

2003 - present United States and Canadian Academy of Pathology

2009 - present American Association for Cancer Research

## PEER REVIEWED PUBLICATIONS

1. Stohr BA, Kreuzer KN. 2001. Repair of topoisomerase-mediated DNA damage in bacteriophage T4. *Genetics* 158:19-28.
2. George JW\*, Stohr BA\*, Tomso DJ, Kreuzer KN. 2001. The tight linkage between DNA replication and double-strand break repair in bacteriophage T4. *PNAS* 98:8290-8297. \*co-first authors
3. Stohr BA, Kreuzer KN. 2002. Coordinated repair of DNA ends during double-strand break repair in bacteriophage T4. *Genetics* 162:1019-1030.
4. Stohr BA, Blackburn EH. 2008. ATM is a key mediator of mutant telomerase RNA cytotoxicity in human cancer cells. *Cancer Research* 68:5309-53017.
5. Stohr BA, Xu L, Blackburn EH. 2010. The terminal telomeric DNA sequence determines the mechanism of dysfunctional telomere fusion. *Molecular Cell* 39:307-314.
6. Vergara-Lluri ME, Stohr BA, Puligandla B, Brenholz P, Horvai AE. 2012. A novel sarcoma with dual differentiation: clinicopathologic and molecular characterization of a combined synovial sarcoma and extraskeletal myxoid chondrosarcoma. *Am J Surg Pathol* 36:1093-1098.
7. Almond JR\*, Stohr BA\*, Panigrahi AK, Albrecht DW, Nelson SW, Kreuzer KN. 2013. Coordination and processing of DNA ends during double-strand break repair: The role of the bacteriophage T4 Mre11/Rad50 (MR) complex. *Genetics* 195:739-755. \*co-first authors
8. Diolaiti ME, Cimini BA, Kageyama R, Charles FA, Stohr BA. 2013. In situ visualization of telomere elongation patterns in human cells. *Nucleic Acids Res* 41:e176.
9. Flach J, Bakker ST, Mohrin M, Conroy PC, Pietras EM, Reynaud D, Alvarez S, Diolaiti ME, Ugarte F, Camilla Forsberg E, Le Beau MM, Stohr BA, Mendez J, Morrison CG, Passegue E. 2014. Replication stress is a potent driver of functional decline in aging and hematopoietic stem cells. *Nature* 512:198-202.
10. Mar F, Debnath J, Stohr BA. 2015. Autophagy-independent senescence and genome instability driven by targeted telomere dysfunction. *Autophagy* 11:527-537.
11. Frank AK, Tran DC, Qu RW, Stohr BA, Segal DJ, Xu L. 2015. The shelterin TIN2 subunit mediates recruitment of telomerase to telomeres. *PLOS Genetics* 11:e1005410.
12. Barfoot T, Herdendorf TJ, Behning BR, Stohr BA, Gao Y, Kreuzer KN, Nelson SW. 2015. Functional analysis of the bacteriophage T4 Rad50 homolog (gp46) coiled-coil domain. *J Biol Chem* 290:23905-23915.
13. Vukovic LD, Jevtic P, Zhang Z, Stohr BA, Levy DL. 2016. Nuclear size is sensitive to NTF2 protein levels in a manner dependent on Ran binding. *J Cell Sci* 129:1115-1127.
14. Liu SY, Joseph NM, Ravindranathan A, Stohr BA, Greenland NY, Vohra P, Hosfield E, Yeh I, Talevich E, Onodera C, Van Ziffle JA, Grenert JP, Bastian BC, Chen YY, Krings G. 2016. Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1

and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity. *Mod Pathol* 29:1012-1027.

15. Calio A, Grignon DJ, Stohr BA, Williamson SR, Eble JN, Cheng L. 2017. Renal cell carcinoma with TFE3 translocation and succinate dehydrogenase B mutation. *Mod Pathol* 30:407-415.
16. Leapman MS, Cowan JE, Simko J, Roberge G, Stohr BA, Carroll PR, Cooperberg MR. 2016. Application of a prognostic Gleason grade grouping system to assess distant prostate cancer outcomes. *Eur Urol* 71:750-759.
17. Rudzinski ER, Lockwood CM, Stohr BA, Vargas SO, Sheridan R, Black JO, Rajaram V, Laetsch TW, Davis JL. 2018. Pan-Trk immunohistochemistry identifies NTRK rearrangements in pediatric mesenchymal tumors. *Am J Surg Pathol* 42:927-935.
18. Sirohi D, Vaske C, Sanborn Z, Smith SC, Don MD, Lindsey KG, Federman S, Vankalakunti M, Koo J, Bose S, Peralta-Venturina M, Ziffle JV, Grenert JP, Miller S, Chiu C, Amin MB, Simko JP, Stohr BA, Luthringer DJ. 2018. Polyoma virus-associated carcinomas of the urologic tract: a clinicopathologic and molecular study. *Mod Pathol* 31:1429-1441.
19. Leapman MS, Nguyen HG, Cowen JS, Xue L, Stohr B, Simko J, Cooperberg MR, Carroll PR. 2018. Comparing prognostic utility of a single-marker immunohistochemistry approach with commercial gene expression profiling following radical prostatectomy. *Eur Urol* 74:668-675.
20. Ravindranathan A, Cimini B, Diolaiti ME, Stohr BA. Preliminary development of an assay for detection of TERT expression, telomere length, and telomere elongation in single cells. *PLoS One* 13:e0206525.
21. Davis JL, Lockwood CM, Stohr B, Boecking C, Al-Ibraheemi A, DuBois SG, Vargas SO, Black JO, Cox MC, Luquette M, Turpin B, Szabo S, Laetsch TW, Albert CM, Parham DM, Hawkins DS, Rudzinski ER. 2018. Expanding the spectrum of pediatric NTRK-rearranged mesenchymal tumors. *Am J Surg Pathol*. In Press.

## REVIEW ARTICLES

1. Xu L, Li S, Stohr BA. 2013. The role of telomere biology in human cancer. *Annu Rev Pathol*. 8:49-78.